We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nanometrics Inc | NASDAQ:NANO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 35.33 | 34.00 | 35.30 | 0 | 01:00:00 |
Updated shareholder composition
Regulatory News:
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its half year results for the six months ended 30 June 2016 and outlines its updated share capital breakdown as of 30 June 2016.
Laurent Levy, CEO of Nanobiotix, commented: “We are pleased with the progress made during the first half of 2016. The company has announced successful clinical results from our Phase I/II Trial of NBTXR3 in Head & Neck Cancer, bringing us a step closer to proving the transferability of our approach across other cancers. The private placement completed in March 2016 enabled new investors, mainly from the US, to invest in Nanobiotix and puts us in a strong position to remain well funded until mid-2017. The promising proof of concept results for our new immuno-oncology preclinical research program show that NBTXR3 may also enhance immunogenicity of the tumor. We expect this momentum of positive clinical and operational developments to continue in the coming months.”
Financial highlights
Financial events
Operational highlights
Post period end main highlights
Financial Review (IFRS)
The detailed Profit & Loss financial statement is laid out below: 6 months period closed on : (€ ‘000) June 30 2016 June 30 2015 Operating revenue 982 91 Other revenue 2,054 1,568 Subsidies 63 139 Research Tax Credit 1,991 1,429 Total revenue 3,036 1,659 Cost of sales - - R&D costs -8,209 -6,124 General costs -3,773 -2,848 Costs associated with payments in shares -1,127 -559 Core operating loss -10,073 -7,872 Income from cash 35 116 Gross cost of debt -49 -4 Net cost of debt -14 112 Other financial income 15 3 Other financial expenses -6 -16 Core pre-tax loss -10,079 -7,773 Tax -89 - Net loss -10,169 -7,773 Profit and loss recognized directly in shareholders' equity 21 211 Foreign exchange translation adjustments 5 -5 Global results -10,143 -7,567 Diluted earning per share -0.68 -0.52Total revenue for H1 2016 amounts to €3,036k (H1 2015: €1,659k) mainly due to:
Total operating expenses as of 30 June 2016 reached €13.1m (H1 2015: €9.6m) due to:
The core operating loss amounts to €10m (H1 2015: €7.9m) in line with expectations. This operating loss increased sharply and remains in close correlation with Nanobiotix’s business and activities.
The total net loss amounts to €10.2m.
Cash balance as of 30 June 2016 was €25m as per expectations.
The shareholding structure remains similar to how it was in December 31, 2015. However, following the successful completion of the private placement in March 2016, the majority of new qualified and institutional investors that became shareholders are based in the US. This has altered the composition of the Company’s institutional investors.
In total, institutional investors now hold 43% of the shareholding (vs. 38% previously) and family offices hold 9% (vs. 13% previously).
Finally, retail and management shareholders remained at the same level with 42% and 6% respectively.
●●●
Next financial press release: revenue for the third quarter of 2016 on November 15, 2016.
●●●
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck cancer, prostate cancer, rectal cancer (PharmaEngine) and liver cancers (HCC and liver metastases). The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
For more information, please visit www.nanobiotix.com
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.16-0732 on July 22, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160831006243/en/
NanobiotixSarah GaubertHead of Communication and Public Affairs+33 (0)1 40 26 07 55contact@nanobiotix.comorMedia relationsFrance - NewCapAnnie-Florence Loyer+33 (0)6 88 20 35 59afloyer@newcap.frorEU Outside France - Instinctif PartnersMelanie Toyne Sewell+44 (0) 207 457 2020nanobiotix@instinctif.comorUnited States – The Ruth GroupKirsten Thomas / Chris Hippolyte+1 508-280-6592 / +1 646-536-7023Nanobiotix@theruthgroup.com
1 Year Nanometrics Chart |
1 Month Nanometrics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions